Retatrutide

$169.00
Item is in stockHurry! Low InventoryItem is out of stock. Item is unavailable
Size
Quantity
Proper Handling

Sterile lyophilized powder in a multi-dose vial. Store at controlled room temperature between 20°C and 25°C (68°F - 77°F), protected from light. Reconstitute with bacteriostatic water; do not shake, allow to dissolve naturally or gently swirl. Once mixed, refrigerate the solution at 2°C - 8°C (36°F - 46°F) and use within 30 days. Purity meets or exceeds U.S. Pharmacopeia (USP) regulations and requirements, with every batch undergoing first and third-party testing. Scroll down to view FAQs.

Questions?

Schedule a consultation with a practitioner specialized in peptide therapy, who will determine the best plan for you.

Retatrutide is an investigational treatment for obesity that is a triple hormone receptor agonist. Retatrutide is a gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist.

Retatrutide works in the treatment of obesity by targeting three different hunger regulating hormones:

  • GIP (gastric inhibitory peptide or glucose-dependent insulinotropic polypeptide) is an incretin hormone that is released from the gut after eating. It stimulates the beta-cells in the pancreas to secrete insulin.
  • GLP-1 (glucagon-like peptide-1) is also an incretin hormone that stimulates the beta-cells to secrete insulin.
  • Glucagon is a hormone secreted from the alpha-cells in the pancreas. It stimulates glucose production in the liver and helps maintain adequate plasma glucose concentrations.

The drug has been nicknamed 'triple G' because it is an agonist of all three receptors.

CAS Number 2381089-83-2

PubChem CID 474492335

Molecular Weight 4845.44 g/mol

Molecular Formula C223H343F3N46O70

Synonyms LY-3437943, NOP2Y096GV

GCGR agonists(Glucagon receptor agonists),GIPR agonists(Gastric inhibitory polypeptide receptor agonists),GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Storage (Lyophilized) At 39 Fahrenheit: 2 years
At -4 Fahrenheit: 3 years

  1. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi: 10.1016/S0140-6736(23)01053-X
  2. Urva S, O’Farrell L, Du Y, et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab. 2023;25(9):2784-2788. doi: 10.1111/dom.15167
  3. Sinha B, Ghosal S, Mukhopadhyay S, et al. Glucagon-related advancements in diabetes therapy. J Diabetol. 2023;14:S16-S18. doi: 10.4103/jod.jod_96_23

Frequently Asked Questions

Retatrutide

Free Shipping

on all orders over $200 delivered straight to your doorstep

Easy Consults

Ongoing care available, 100% online at your convenience

Quality First

All peptides are clinical grade and undergoes third-party testing

Proactive Care

Your journey, your way. We are here to support your health goals.

support_your_whole_body_1.png

Your body, your journey.

Millions of people want to know how peptide therapy can help achieve optimal health and performance.

Speak with licensed physicians and specialists in peptide therapy about proper dosage, reconstituting lyophilized peptides, titrating up (or down), and proper care and consideration of your medical history.